Dr. Reddy's Receives US FDA Approval for Rituximab Biosimilar

Dr. Reddy's Laboratories has received approval from the U.S. Food and Drug Administration (FDA) for its rituximab biosimilar, paving the way for its commercial launch in the United States.

What Happened and Why It Matters

The U.S. FDA approved Dr. Reddy's rituximab biosimilar, allowing the company to expand its biosimilars portfolio in one of the world's largest pharmaceutical markets.

The biosimilar is approved as a reference product for Rituxan® (rituximab), a biologic medicine used in the treatment of several B-cell malignancies and autoimmune diseases.

The approval follows a successful Pre-License Inspection (PLI) of the company's biologics manufacturing facility in Bachupally, Hyderabad, where Dr. Reddy's demonstrated compliance with U.S. regulatory standards.

Commercialization Partnership Strengthens U.S. Presence

• FDA Approval: Dr. Reddy's has received U.S. FDA approval for its rituximab biosimilar.
• Exclusive U.S. Partner: Fresenius Kabi holds the exclusive rights to commercialize the product in the United States.
• Global Presence: The rituximab biosimilar is already marketed in India, the European Union, the United Kingdom, and more than 25 other countries.
• Regulatory Milestone: The approval follows the successful inspection of Dr. Reddy's biologics manufacturing facility in Hyderabad, confirming compliance with U.S. FDA standards.
• Portfolio Expansion: The approval strengthens Dr. Reddy's global biosimilars business and expands its presence in the U.S. pharmaceutical market.

What to Watch Next

Investors will monitor the commercial launch timeline of the rituximab biosimilar in the United States and its contribution to Dr. Reddy's biosimilars revenue.

The company's continued progress in developing and commercializing complex biologic medicines for regulated global markets will also remain an important area of focus.